Q4 2019 13F Holders as of 12/31/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
127
-
Total 13F shares, excl. options
-
31.1M
-
Shares change
-
-5.55M
-
Total reported value, excl. options
-
$272M
-
Value change
-
-$65.2M
-
Put/Call ratio
-
1.1
-
Number of buys
-
71
-
Number of sells
-
-58
-
Price
-
$8.75
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q4 2019
173 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q4 2019.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 127 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.1M shares
of 49.6M outstanding shares and own 62.61% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (3.99M shares), STATE STREET CORP (3.51M shares), BlackRock Inc. (2.89M shares), MILLENNIUM MANAGEMENT LLC (1.85M shares), FRED ALGER MANAGEMENT, LLC (1.77M shares), Palo Alto Investors LP (1.35M shares), Nuveen Asset Management, LLC (1.28M shares), ACADIAN ASSET MANAGEMENT LLC (839K shares), FEDERATED HERMES, INC. (824K shares), and GOLDMAN SACHS GROUP INC (768K shares).
This table shows the top 127 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.